120 related articles for article (PubMed ID: 30465366)
1. Bladder Cancer In Patients With Type 2 Diabetes Treated With Pioglitazone, A Comparative Study.
Riaz A; Khan K; Afreen B; Kazmi I
J Ayub Med Coll Abbottabad; 2018; 30(3):356-359. PubMed ID: 30465366
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer with pioglitazone: A case-control study.
Malhotra B; Hiteshi P; Khalkho P; Malik R; Bhadada SK; Bhansali A; Shafiq N; Malhotra S; Kumar N; Rajput R; Rastogi A
Diabetes Metab Syndr; 2022 Nov; 16(11):102637. PubMed ID: 36270237
[TBL] [Abstract][Full Text] [Related]
3. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
[TBL] [Abstract][Full Text] [Related]
4. A word of caution regarding pioglitazone.
Usman MS; Rizwan T; Ahmed F
J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979
[No Abstract] [Full Text] [Related]
5. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
[TBL] [Abstract][Full Text] [Related]
7. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
[TBL] [Abstract][Full Text] [Related]
9. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
Jin SM; Song SO; Jung CH; Chang JS; Suh S; Kang SM; Jung I; Park CY; Kim JH; Cho JH; Lee BW
J Korean Med Sci; 2014 Feb; 29(2):238-42. PubMed ID: 24550651
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
11. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
13. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
14. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
15. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
Ryder RE
Diabet Med; 2015 Mar; 32(3):305-13. PubMed ID: 25472014
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
18. Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
Qu H; Zheng Y; Wang Y; Zhang R; Ruan X; Yang G; Liu Z; Zheng H
Sci Rep; 2017 Nov; 7(1):15804. PubMed ID: 29150684
[TBL] [Abstract][Full Text] [Related]
19. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone use and the risk of bladder cancer.
Kuo HW; Tiao MM; Ho SC; Yang CY
Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
